Filtered By:
Therapy: Antiviral Therapy
This page shows you your search results in order of date. This is page number 9.
Order by Relevance | Date
Total 305 results found since Jan 2013.
Immune Responses to MERS-CoV in Humans and Animals
Adv Exp Med Biol. 2021;1313:85-97. doi: 10.1007/978-3-030-67452-6_5.ABSTRACTMiddle East Respiratory Syndrome Coronavirus (MERS-CoV) is an emerging zoonotic coronavirus that circulates in dromedary camels and sporadically transmit into humans, subsequently resulting in community and nosocomial cases. The viral infection in humans has a range of disease severity from asymptomatic to severe pneumonia and death, whereas the infection in camels is usually asymptomatic. There is no approved antiviral therapy or vaccine for MERS-CoV infections although there have been a number of therapeutic and vaccine candidates under developme...
Source: Advances in Experimental Medicine and Biology - October 18, 2021 Category: Research Authors: Naif Khalaf Alharbi Swarali S Kulkarni Darryl Falzarano Source Type: research
Application of Copper Iodide Nanoparticle-doped Film and Fabric to Inactivate SARS-CoV-2 via the Virucidal Activity of Cuprous Ion (Cu < sup > + < /sup > )
This study provides novel information about the utility and mechanisms of action of promising virucidal material against SARS-CoV-2.PMID:34613751 | DOI:10.1128/AEM.01824-21
Source: Applied and Environmental Microbiology - October 6, 2021 Category: Microbiology Authors: Yohei Takeda Dulamjav Jamsransuren Tomokazu Nagao Yoko Fukui Sachiko Matsuda Haruko Ogawa Source Type: research
Crystal structures of human coronavirus NL63 main protease at different pH values
Human coronavirus NL63 (HCoV-NL63), which belongs to the genus Alphacoronavirus, mainly infects children and the immunocompromized and is responsible for a series of clinical manifestations, including cough, fever, rhinorrhoea, bronchiolitis and croup. HCoV-NL63, which was first isolated from a seven-month-old child in 2004, has led to infections worldwide and accounts for 10% of all respiratory illnesses caused by etiological agents. However, effective antivirals against HCoV-NL63 infection are currently unavailable. The HCoV-NL63 main protease (Mpro), also called 3C-like protease (3CLpro), plays a vital role in mediating...
Source: Acta Crystallographica Section F - September 27, 2021 Category: Biochemistry Authors: Gao, H. Zhang, Y. Jiang, H. Hu, X. Zhang, Y. Zhou, X. Zhong, F. Lin, C. Li, J. Luo, J. Zhang, J. Tags: coronaviruses human coronavirus NL63 main protease crystallization apo structure research communications Source Type: research
SARS-Coronavirus 2, A Metabolic Reprogrammer: A Review in the Context of the Possible Therapeutic Strategies
Curr Drug Targets. 2021 Sep 16. doi: 10.2174/1389450122666210917113842. Online ahead of print.ABSTRACTNovel coronavirus, SARS-CoV-2 is advancing at a staggering pace to devastate the health care system and foster the concerns over public health. In contrast to the past outbreaks, coronaviruses aren't clinging themselves as a strict respiratory virus. Rather, becoming a multifaceted virus, it affects multiple organs by interrupting a number of metabolic pathways leading to significant rates of morbidity and mortality. Following infection they rigorously reprogram multiple metabolic pathways of glucose, lipid, protein, nucle...
Source: Current Drug Targets - September 17, 2021 Category: Drugs & Pharmacology Authors: Poornima Gopi T R Anju Vinod Soman Pillai Mohanan Veettil Source Type: research
Clinical outcome of patients with COVID-19 Pneumonia treated with corticosteroids and colchicine in Colombia
To date, there is no specific antiviral therapy for severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) that causes Coronavirus disease 2019 (Covid-19). Since there is no specific therapy against SARS...
Source: Annals of Clinical Microbiology and Antimicrobials - September 14, 2021 Category: Microbiology Authors: Miguel Alejandro Pinz ón, Doris Cardona Arango, Juan Felipe Betancur, Santiago Ortiz, Héctor Holguín, Carolina Arias Arias, Bernardo J. Muñoz Palacio, Michael Amarillo, Juan Felipe Llano and Pablo Montoya Tags: Research Source Type: research
Favipiravir Versus Arbidol for Clinical Recovery Rate in Moderate and Severe Adult COVID-19 Patients: A Prospective, Multicenter, Open-Label, Randomized Controlled Clinical Trial
Conclusion: Among patients with COVID-19, favipiravir, compared to Arbidol, did not significantly improve the clinical recovery rate at day 7. Favipiravir significantly improved the latency to relieve pyrexia and cough. Adverse effects caused by favipiravir are mild and manageable.
Source: Frontiers in Pharmacology - September 2, 2021 Category: Drugs & Pharmacology Source Type: research
Clinical efficacy and safety of combination therapy of tocilizumab and steroid pulse therapy for critical COVID-19 in HD patients
ConclusionTCZ combined with mPSL pulse therapy improved the survival rate without significant adverse events in critical HD and non-HD patients with COVID-19 by strongly suppressing systemic hyperinflammation.
Source: Clinical and Experimental Nephrology - August 26, 2021 Category: Urology & Nephrology Source Type: research
